Prodrug compounds and their uses

Patent metadata

Field	Value
Publication number	US-11278559-B2
Application number	US-201916557768-A
Country	US
Kind code	B2
Filing date	Aug 30, 2019
Priority date	Feb 13, 2014
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

First claim

What is claimed is:

1. A compound of Formula IV:

wherein:
R 41 is H; or R 41 optionally forms a bond with M or X 4 when X 4 is N;
Z 4 is selected from the group consisting of CR 46 R 47 , C(O), C(O)O, C(O)NR 48 , SO 2 , an optionally substituted aryl, and an optionally substituted heteroaryl;
R 42 , R 43 , R 44 , R 45 , R 46 , and R 47 are each independently selected from the group consisting of H, OH, amino, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 alkyloxy, an optionally substituted C 1 -C 6 acyloxy, an optionally substituted C 1 -C 6 hereroalkyl, an optionally substituted phosphate, an optionally substituted phosphonate, an optionally substituted aryl, and an optionally substituted heterocycle; or R 44 and R 45 are independently or together optionally linked with R 42 , R 43 , R 46 , or R 47 to form an optionally substituted ring; or R 44 is M; or R 44 and R 45 are together optionally to form an oxo (═O) or its derivative;
M is a biological agent or part of a biological agent or a prodrug of a biological agent;
X 4 is selected from the group consisting of O, NR 48 , NC(O)R 48 , NS(O) 2 R 49 , and NP(O)(R 50 ) 2 ;
R 48 is selected from the group consisting of H, an optionally substituted C 1 -C 6 alkyl, and an optionally substituted C 1 -C 6 heteroalkyl;
R 49 is selected from the group consisting of NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 50 is selected from the group consisting of OH, NH 2 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 alkyloxy, and an optionally substituted C 1 -C 6 alkylamino;
n is 0, 1, 2, or 3;
or a stereoisomer or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

3. A method of treating a disease, disorder or condition comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.

4. The method of claim 3 , wherein the disease, disorder or condition is a disease, disorder or condition of the liver.

5. The method of claim 3 , wherein the disease, disorder or condition is a metabolic, cardiovascular or hormonal disease in which the liver is involved in the production and/or the homeostasis control of the biochemical end products of the disease, disorder or condition.

6. The method of claim 3 , wherein the disease, disorder or condition is selected from the group consisting of hepatitis, liver cancer, liver fibrosis, fatty liver, malaria, viral infection, parasitic infection, diabetes, hyperlipidemia, atherosclerosis, obesity, dyslipidemia, hyperglycemia and a hormonal condition.

7. The method of claim 3 , further comprising administering an effective amount of at least one additional therapeutic agent to the subject in need thereof.

8. The method of claim 3 , wherein the subject is a mammal.

9. The method of claim 3 , wherein the subject is human.

10. A method of delivering a diagnostic imaging agent to the liver of a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 .

11. The method of claim 10 , wherein the subject is a mammal.

12. The method of claim 10 , wherein the subject is human.

13. A method of inhibiting viral replication in a cell comprising contacting the cell with a compound of claim 1 .

14. The method of claim 13 , wherein the cell is in vivo.

15. The method of claim 13 , wherein the cell is ex vivo.

16. The method of claim 13 , wherein the cell is a hepatocyte.

17. The method of claim 13 , wherein the cell is mammalian.

18. The method of claim 13 , wherein the cell is human.

19. A method of intervening in a molecular pathway or modulating a target in a cell comprising contacting the cell with a compound of claim 1 .

20. The method of claim 19 , wherein the cell is in vivo.

21. The method of claim 19 , wherein the cell is ex vivo.

22. The method of claim 19 , wherein the cell is a hepatocyte.

23. The method of claim 19 , wherein the cell is mammalian.

24. The method of claim 19 , wherein the cell is human.

Assignees

• Ligand Pharm Inc

Inventors

• Zhi Lin

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/661 Primary

  Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos} · CPC title

• C07D317/24

  esterified · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title